# Intravenous Iron Isomaltoside versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy

# Inclusion/Exclusion Criteria Form REB # 21-64 HC6-24-c260086

Participant ID:	(Code	Date: MMM/DD/YYYY	Obstetrical Care Provider (Please Print):
Supplied to Parti	icipant) XXX		

#### **Inclusion Criteria**

Patient <u>must meet ALL</u> of the following criteria to be eligible for enrolment as a study participant:

	Yes	No
<ul> <li>Pregnant woman at GA ≥ 13 weeks</li> </ul>		
● Age ≥ 18 years		
<ul> <li>Iron/TIBC (TSAT) &lt;20%</li> </ul>		
• Serum ferritin <30ug/L		
• Hb <110 g/L		
• Willing to participate and attend all planned appointments, follow-up visits (at baselin during infusion, during delivery, and six weeks postpartum) and planned blood wor		

## **Exclusion Criteria**

If patient meets *any* of these criteria, patient is <u>not</u> eligible for enrolment as a study participant:

	Yes	No
• Pregnancy with GA <13 weeks		
<ul> <li>Does not meet defining criteria for IDA [Iron/TIBC (TSAT) &lt; 20%, Serum Ferritin &lt;30ug/L, Hb &lt;110g/L]</li> </ul>		
• Age <18 years		
History of anemia caused by thalassemia or others haematologic disorder other than iron deficiency anemia		
Known serious hypersensitivity to other parental iron products		
History of multiple allergies (drug, environmental, food)		
<ul> <li>Iron overload or disturbances in utilization of iron (example: haemochromatosis and haemosiderosis)</li> </ul>		
Decompensated liver cirrhosis or active hepatitis		

		Yes	No
•	Active acute infection or chronic infection		
•	Treated with IV iron products or blood transfusion within 4 weeks prior to inclusion		
•	Participant in any other interventional/concurrent trial		 
•	Multiple gestation pregnancy (twins, triplets)		
Signifi •	cant comorbidities: Asthma/Lung Disease		
•	Heart Disease		
•	Kidney Disease		
•	Rheumatologic disease		
•	Cancer		
•	Known hypersensitivity to iron sucrose or iron isomaltoside or any of its excipients		
•	Known allergies or sensitivities to oral iron		

#### Fax form to: 306-766-3328

Email form to: patientbloodmanagement@saskhealthauthority.ca (confidential email)

May we contact you if more information needed? Yes  $\square$  No  $\square$ Best contact information: Telephone: \_\_\_\_\_ Email:

#### Form Completed by:\_\_\_\_\_ Date:\_\_\_\_\_

## **<u>Clinical Trial Coordinator Only:</u>**

Clinical Trial Coordinator Signature:	Date:	
Copy of signed ICF on file	Date verified:	Initials:
Copy of Inclusion/Exclusion criteria form on file	Date verified:	Initials:
Patient education documents sent to patient	Date verified:	Initials:
Patient information placed in confidential database	Date verified:	Initials:
Confirmation of enrolled patient sent to obstetrical care provider	Date verified:	Initials:
Copy of completed PPO sent to Infusion Clinic and to MBU	Date verified:	Initials: